Outcomes of Different Management Approaches for Preterm Infants with Patent Ductus Arteriosus: Implications for Optimal Timing of Surgical Closure
Presented During:
Monday, May 8, 2023: 8:30AM - 8:45AM
Los Angeles Convention Center
Posted Room Name:
403B
Abstract No:
206
Submission Type:
Abstract Submission
Authors:
Won Young Lee (1), Sook Kyung Yum (2), Yu-Mi Seo (2), Sol Kim (2), Ju Ae Shin (2), Cheul Lee (1)
Institutions:
(1) Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital, Seoul, South Korea, (2) Department of Pediatrics, Seoul St. Mary's Hospital, Seoul, South Korea
Submitting Author:
Won Young Lee
-
Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital
Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital
Co-Author(s):
Sook Kyung Yum
-
Contact Me
Department of Pediatrics, Seoul St. Mary's Hospital
Department of Pediatrics, Seoul St. Mary's Hospital
Yu-Mi Seo
-
Contact Me
Department of Pediatrics, Seoul St. Mary's Hospital
Department of Pediatrics, Seoul St. Mary's Hospital
Sol Kim
-
Contact Me
Department of Pediatrics, Seoul St. Mary's Hospital
Department of Pediatrics, Seoul St. Mary's Hospital
Ju Ae Shin
-
Contact Me
Department of Pediatrics, Seoul St. Mary's Hospital
Department of Pediatrics, Seoul St. Mary's Hospital
Cheul Lee
-
Contact Me
Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital
Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital
Presenting Author:
Won Young Lee
-
Contact Me
N/A
N/A
Abstract:
Objective: To evaluate neonatal outcomes depending on different treatment strategies for hemodynamically significant patent ductus arteriosus (hsPDA) in preterm very-low-birth-weight (VLBW) infants, in regard to treatment time point.
Methods: This retrospective cohort study was conducted including 430 preterm infants with PDA (186 hsPDA, 43.3%) born between September 2014 and January 2021. Outcomes were compared between treatment strategies (277 conservative vs 153 active). To identity the optimal timing of surgical closure, surgical patients were classified in three subgroups: early primary closure (≤14 post-natal age), late primary closure (>14 post-natal age), and secondary closure after failed pharmacological closure. Adjusted linear logistic regression was conducted to analyze risk factors for in-hospital death, bronchopulmonary dysplasia, post-ligation cardiac syndrome, and acute kidney injury. Significant risk factors were adjusted to identify the optimal period for surgical closure by non-linear regression model.
Results: Active treatment group showed significantly lower in-hospital death compared to the conservative treatment group in overall (adjusted odd ratio (aOR), 0.29; p=0.002) and when subanalyzed in infants with hsPDA (aOR, 0.22; p=0.003). With non-linear regression, the primary surgical closure group presented lower probability for the composite outcome of in-hospital death or bronchopulmonary dysplasia when postmenstrual age was greater than 28 weeks, compared to the secondary closure group. In terms of postoperative complications, the probability for composite outcome of post-ligation cardiac syndrome or acute kidney injury was also lower in the primary closure group when postmenstrual age was less than 32 weeks, compared to the secondary closure group. At postmenstrual age 28 to 32 weeks, early primary closure group experienced the most benefit in terms of in-hospital death or bronchopulmonary dysplasia (early 51.5% vs late 82.1% vs secondary 82.3%, p<0.001) and post-ligation syndrome or acute kidney injury (early 17.8% vs late 22.6% vs secondary 38.4%, p<0.001).
Conclusion: Considering in-hospital death, active treatment is recommended in VLBW infants with hsPDA. In particular, primary surgical closure rather than secondary closure provides maximal benefit and minimal risk of surgery at postmenstrual age 28 to 32 weeks, implying that this could serve as the optimal timing for primary surgical closure of hsPDA in VLBW infants.
Methods: This retrospective cohort study was conducted including 430 preterm infants with PDA (186 hsPDA, 43.3%) born between September 2014 and January 2021. Outcomes were compared between treatment strategies (277 conservative vs 153 active). To identity the optimal timing of surgical closure, surgical patients were classified in three subgroups: early primary closure (≤14 post-natal age), late primary closure (>14 post-natal age), and secondary closure after failed pharmacological closure. Adjusted linear logistic regression was conducted to analyze risk factors for in-hospital death, bronchopulmonary dysplasia, post-ligation cardiac syndrome, and acute kidney injury. Significant risk factors were adjusted to identify the optimal period for surgical closure by non-linear regression model.
Results: Active treatment group showed significantly lower in-hospital death compared to the conservative treatment group in overall (adjusted odd ratio (aOR), 0.29; p=0.002) and when subanalyzed in infants with hsPDA (aOR, 0.22; p=0.003). With non-linear regression, the primary surgical closure group presented lower probability for the composite outcome of in-hospital death or bronchopulmonary dysplasia when postmenstrual age was greater than 28 weeks, compared to the secondary closure group. In terms of postoperative complications, the probability for composite outcome of post-ligation cardiac syndrome or acute kidney injury was also lower in the primary closure group when postmenstrual age was less than 32 weeks, compared to the secondary closure group. At postmenstrual age 28 to 32 weeks, early primary closure group experienced the most benefit in terms of in-hospital death or bronchopulmonary dysplasia (early 51.5% vs late 82.1% vs secondary 82.3%, p<0.001) and post-ligation syndrome or acute kidney injury (early 17.8% vs late 22.6% vs secondary 38.4%, p<0.001).
Conclusion: Considering in-hospital death, active treatment is recommended in VLBW infants with hsPDA. In particular, primary surgical closure rather than secondary closure provides maximal benefit and minimal risk of surgery at postmenstrual age 28 to 32 weeks, implying that this could serve as the optimal timing for primary surgical closure of hsPDA in VLBW infants.
CONGENTIAL:
Neonatal and Pediatric Cardiac Surgery
Image or Table
